By: IPP Bureau
Last updated : May 24, 2025 12:07 pm
For the full year FY25, net profit soared 12x to Rs 345 crore
Strides Pharma Science announced its consolidated financial results for the quarter (Q4FY25) and full year (FY25) ended March 31, 2025. The company reported a five-fold jump in its the net profit to Rs 113 crore in Q4 FY25 from Rs 24.2 crore a year earlier, while the revenue climbed by 17% YoY to Rs 1,190.4 crore. EBITDA grew 22% on year to Rs 218 crore, with margins expanding 75 basis points to 18.3%.
The company’s US revenue surged 23.2% YoY to $77 million, supported by new product launches and a stable base business.
For the full year FY25, net profit soared 12x to Rs 345 crore, with revenue up 17.2% at Rs 4565.3 crore. EBITDA for the year rose 36.8% to Rs 802.8 crore, and the EBITDA margin improved by 252 basis points to 17.6%.
Arun Kumar, Founder & Non-Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, "We are pleased to report a strong close to FY25, having successfully exceeded the outlook communicated across all key parameters. Our FY25 revenue grew by 17.2% YoY, outperforming our guidance of 12–15%, aided by strong US business performance. We also surpassed our EBITDA outlook, delivering Rs. 802.8 crore in FY25, reflecting enhanced operational efficiency and margin resilience post-demerger.
We reduced Net debt by Rs. 512.8 crore, and our Net Debt-to-EBITDA ratio improved to 1.9x, well below the outlook given. The US business recorded $291million in revenue, representing 21.8% YoY growth and exceeding the outlook. This was propelled by new product launches, steady base business, and a strong commercial execution framework. We also delivered an operating PAT of Rs. 344.7 crore for FY25, reflecting continued focus on profitability.
The Board has recommended a dividend of ₹4 per share for FY25, reflecting our strong financial performance. As we look ahead, we remain focused on the disciplined execution of our business strategies, underpinned by strong governance and a deep commitment to ESG — all aimed at delivering superior business outcomes and creating long-term value for all stakeholders."